Pacritinib citrate 新

参考资料仅供科学研究，不可用于个人用途。

货号：BCP48998CAS号：1228923-42-9纯度：98%

规格	价格(CNY)	是否现货	购买咨询
10.00 mg	￥1000.00	In-stock	购买咨询
25.00 mg	￥1650.00	In-stock	购买咨询
100.00 mg	￥3200.00	In-stock	购买咨询

在线咨询

大批量询价

全国免运费！免费咨询：400-099-8200 或手机联系：13472751340

* 必填项

请填妥以下表格,您将在一分钟内得到邮件机器人给你的报价。

Product name			* Applicant name
Catalog Number			* Institution/Company
* Email address			Phone number
Country			* Quantity Required
Remarks

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name			* Applicant name
Catalog Number			* Institution/Company
* Email address			Phone number
Country			* Quantity Required
Remarks

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name			* Applicant name
Catalog Number			* Institution/Company
* Email address			Phone number
Country			* Quantity Required
Remarks

基本信息与产品描述

CAS号	1228923-42-9	货号	BCP48998
中文名	Pacritinib citrate
英文名	Pacritinib citrate
中文别名
英文别名
SMILES	C1CCN(C1)CCOC2=C3COCC=CCOCC4=CC(=CC=C4)C5=NC(=NC=C5)NC(=C3)C=C2.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
化学名称
分子式	C34H40N4O10	分子量	664.71
纯度	98%	配送	惯例下常温包邮
产品描述	Pacritinib Citrate is the citrate salt form of pacritinib, an orally bioavailable inhibitor of Janus kinase 2 (JAK2), the JAK2 mutant JAK2V617F and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration of pacritinib citrate, pacritinib competes with JAK2 and the JAK2 mutant JAK2V617F for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-signal transducer and activator of transcription (STAT) signaling pathway, and the induction of apoptosis. In addition, pacritinib targets, binds to and inhibits the activity of FLT3. This inhibits FLT3-mediated signaling and the proliferation of FLT3-expressing cancer cells. JAK2, often upregulated or mutated in a variety of cancer cells, plays a key role in tumor cell proliferation and survival. The JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias. In addition, JAK2 and FLT3 play a key role in the regulation of the inflammatory response and dendritic cell (DC) proliferation, differentiation and function. Inhibition of JAK2- and FLT3-mediated signaling may suppress the generation and differentiation of DCs, and may regulate inflammatory and immune responses.

技术资料和支持

Pacritinib citrate 新

关于瀚香生物科技

客服支持

订单

联系瀚香生物科技